Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

ABSTRACT:

Importance

Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incidence has not been evaluated.

Objective

To describe the temporal evolution of PML incidence in France before and after introduction of risk minimization recommendations in 2013.

Design, setting, and participants

This observational study used data in the MS registry OFSEP (Observatoire Français de la Sclérose en Plaques) collected between April 15, 2007, and December 31, 2016, by participating MS expert centers and MS-dedicated networks of neurologists in France. Patients with an MS diagnosis according to current criteria, regardless of age, were e

SUBMITTER: Vukusic S 

PROVIDER: S-EPMC6724170 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature